Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literature

Gynecologic Oncology

Volumn 101, Issue 3, 2006, Pages 464-469

  Pink, Daniel ^a   Lindner, Tanja ^a   Mrozek, Alicia ^a   Kretzschmar, Albrecht ^a   Thuss Patience, Peter C ^b   Dörken, Bernd ^a,b   Reichardt, Peter ^a,b  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b Medizinische Klinik mit Schwerpunkt Hamatologie und Onkologie   (Germany)

Author keywords

Letrozole; Low grade endometrial stromal sarcoma; MPA; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; GESTAGEN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; DRUG EFFICACY; ENDOMETRIUM SARCOMA; ESTROGEN THERAPY; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; LUNG METASTASIS; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; AGED; ENDOMETRIAL STROMAL TUMOR; FEMALE; MIDDLE AGED; PATHOLOGY; PELVIS TUMOR; PERITONEUM TUMOR; RETROSPECTIVE STUDY; UTERUS CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL STROMAL TUMORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NITRILES; PELVIC NEOPLASMS; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TAMOXIFEN; TRIAZOLES; UTERINE NEOPLASMS;

EID: 33745324082     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.11.010     Document Type: Article

References (51)

1. Koss L.G., Spiro R.H., and Brunschwig A. Endometrial stromal sarcoma. Surg. Gynecol. Obstet. 121 (1965) 531-537
2. Harlow B.L., Weiss N.S., and Lofton S. The epidemiology of sarcomas of the uterus. J. Natl. Cancer Inst. 76 (1986) 399-402
3. Haberal A., Kayikcioglu F., Boran N., Caliskan E., Ozgul N., and Kose M.F. Endometrial stromal sarcoma of the uterus: analysis of 25 patients. Eur. J. Obstet. Gynecol. Reprod. Biol. 109 (2003) 209-213
4. Norris H.J., and Taylor H.B. Mesenchymal tumors of the uterus. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 19 (1966) 755-766
5. Gadducci A., Sartori E., Landoni F., Zola P., Maggino T., Urgesi A., et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol. Oncol. 63 (1996) 247-253
6. Melilli G.A., Di Vagno G., Greco P., Vimercati A., Loizzi V., Putignano G., et al. Endometrial stromal sarcoma: a clinicopathologic study. Eur. J. Gynaecol. Oncol. 20 (1999) 33-34
7. Huang K.T., Chen C.A., Tseng G.C., Chen T.M., Cheng W.F., and Hsieh C.Y. Endometrial stromal sarcoma of twenty cases. Acta Obstet. Gynecol. Scand. 75 (1996) 551-555
8. Satoh Y., Ishikawa Y., Miyoshi T., Mukai H., Okumura S., and Nakagawa K. Pulmonary metastases from a low-grade endometrial stromal sarcoma confirmed by chromosome aberration and fluorescence in-situ hybridization approaches: a case of recurrence 13 years after hysterectomy. Virchows Arch. 442 (2003) 173-178
9. Amant F., Moerman P., Cadron I., Hagemeijer A., Vergote I., and Debiec-Rychter M. Endometrial stromal sarcoma with a sole t(X;17) chromosome change: report of a case and review of the literature. Gynecol. Oncol. 88 (2003) 459-462
10. Oliva E., Clement P.B., and Young R.H. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv. Anat. Pathol. 7 (2000) 257-281
11. Amant F., Vergote I., and Moerman P. The classification of a uterine sarcoma as 'high-grade endometrial stromal sarcoma' should be abandoned. Gynecol. Oncol. 95 (2004) 412-413
12. Schwartz S.M., and Thomas D.B. A case-control study of risk factors for sarcomas of the uterus. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Cancer 64 (1989) 2487-2492
13. Bodner K., Bodner-Adler B., Obermair A., Windbichler G., Petru E., Mayerhofer S., et al. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol. Oncol. 81 (2001) 160-165
14. Chu M.C., Mor G., Lim C., Zheng W., Parkash V., and Schwartz P.E. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol. Oncol. 90 (2003) 170-176
15. Omura G.A., Blessing J.A., Major F., Lifshitz S., Ehrlich C.E., Mangan C., et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J. Clin. Oncol. 3 (1985) 1240-1245
16. Etiz D., Garipagaoglu M., Etiz E.E., Kose F.M., Kayikcioglu F., Haberal A., et al. Results of postoperative radiotherapy in the treatment of 29 uterine sarcoma patients. Tumori 89 (2003) 183-188
17. Echt G., Jepson J., Steel J., Langholz B., Luxton G., Hernandez W., et al. Treatment of uterine sarcomas. Cancer 66 (1990) 35-39
18. Berchuck A., Rubin S.C., Hoskins W.J., Saigo P.E., Pierce V.K., and Lewis Jr. J.L. Treatment of endometrial stromal tumors. Gynecol. Oncol. 36 (1990) 60-65
19. Mansi J.L., Ramachandra S., Wiltshaw E., and Fisher C. Endometrial stromal sarcomas. Gynecol. Oncol. 36 (1990) 113-118
20. Weitmann H.D., Knocke T.H., Kucera H., and Potter R. Radiation therapy in the treatment of endometrial stromal sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 49 (2001) 739-748
21. Reed N.S. Uterine sarcomas-The biggest challenge?. Clin. Oncol. (R Coll Radiol) 14 (2002) 50-53
22. Brooks S.E., Zhan M., Cote T., and Baquet C.R. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol. Oncol. 93 (2004) 204-208
23. Piver M.S., Rutledge F.N., Copeland L., Webster K., Blumenson L., and Suh O. Uterine endolymphatic stromal myosis: a collaborative study. Obstet. Gynecol. 64 (1984) 173-178
24. Inayama Y., Shoji A., Odagiri S., Hirahara F., Ito T., Kawano N., et al. Detection of pulmonary metastasis of low-grade endometrial stromal sarcoma 25 years after hysterectomy. Pathol. Res. Pract. 196 (2000) 129-134
25. Tabata T., Takeshima N., Hirai Y., and Hasumi K. Low-grade endometrial stromal sarcoma with cardiovascular involvement-A report of three cases. Gynecol. Oncol. 75 (1999) 495-498
26. Spano J.P., Soria J.C., Kambouchner M., Piperno-Neuman S., Morin F., Morere J.F., et al. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med. Oncol. 20 (2003) 87-93
27. Katz L., Merino M.J., Sakamoto H., and Schwartz P.E. Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol. Oncol. 26 (1987) 87-97
28. Leiser A.L., Hamid A.M., and Blanchard R. Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor. Gynecol. Oncol. 94 (2004) 567-571
29. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI 92 (2000) 205-216
30. Wysowski D.K., Honig S.F., and Beitz J. Uterine sarcoma associated with tamoxifen use. NEJM 346 (2002) 1832-1833
31. Le Bouedec G., Auvray H., Cure H., de Latour M., Penault-Llorca F., and Dauplat J. Uterine sarcoma in patients receiving tamoxifen therapy. Apropos of 2 cases. Rev. Med. Interne 22 (2001) 881-885
32. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., and Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 (1994) 527-537
33. Wickerham D.L., Fisher B., Wolmark N., Bryant J., Costantino J., Bernstein L., et al. Association of tamoxifen and uterine sarcoma. J. Clin. Oncol. 20 (2002) 2758-2760
34. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 (2000) 881-887
35. Bouchardy C., Verkooijen H.M., Fioretta G., Sappino A.P., and Vlastos G. Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen. J. Clin. Oncol. 20 (2002) 4403
36. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., and Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85 (1995) 304-313
37. Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Bergstrom R., Lindgren A., et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst. 91 (1999) 1131-1137
38. Weiderpass E., Baron J.A., Adami H.O., Magnusson C., Lindgren A., Bergstrom R., et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 353 (1999) 1824-1828
39. Kennedy M.M., Baigrie C.F., and Manek S. Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology. Int. J. Gynecol. Pathol. 18 (1999) 130-137
40. Beer T.W., Buchanan R., and Buckley C.H. Uterine stromal sarcoma following tamoxifen treatment. J. Clin. Pathol. 48 (1995) 596
41. Saga Y., Ohwada M., Kohno T., Takayashiki N., and Suzuki M. High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int. J. Gynecol. Cancer 13 (2003) 690-692
42. Eddy G.L., and Mazur M.T. Endolymphatic stromal myosis associated with tamoxifen use. Gynecol. Oncol. 64 (1997) 262-264
43. Pang L.C. Endometrial stromal sarcoma with sex cord-like differentiation associated with tamoxifen therapy. South. Med. J. 91 (1998) 592-594
44. Scribner Jr. D.R., and Walker J.L. Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace. Gynecol. Oncol. 71 (1998) 458-460
45. Pelillo D. Proliferative stromatosis of the uterus with pulmonary metastases. Remission following treatment with a longacting synthetic progestin: a case report. Obstet. Gynecol. 31 (1968) 33-39
46. Krumholz B.A., Lobovsky F.Y., and Halitsky V. Endolymphatic stromal myosis with pulmonary metastases. Remission with progestin therapy: report of a case. J. Reprod. Med. 10 (1973) 85-89
47. Maluf F.C., Sabbatini P., Schwartz L., Xia J., and Aghajanian C. Endometrial stromal sarcoma: objective response to letrozole. Gynecol. Oncol. 82 (2001) 384-388
48. Leunen M., Breugelmans M., De Sutter P., Bourgain C., and Amy J.J. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol. Oncol. 95 (2004) 769-771
49. Pautier P., Genestie C., Fizazi K., Morice P., Mottet C., Haie-Meder C., et al. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas. Int. J. Gynecol. Cancer 12 (2002) 749-754
50. Yamawaki T., Shimizu Y., and Hasumi K. Treatment of stage IV "high-grade" endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin. Gynecol. Oncol. 64 (1997) 265-269
51. Lehrner L.M., Miles P.A., and Enck R.E. Complete remission of widely metastatic endometrial stromal sarcoma following combination chemotherapy. Cancer 43 (1979) 1189-1194